Dr Reddy’s and Sanofi partner to launch Beyfortus, a novel drug to prevent respiratory syncytial virus in infants.

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

ATLANTA (AP) — A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

The U.S. Food and Drug Administration has approved three vaccines for RSV — GSK's Arexvy, Moderna's mRESVIA and Pfizer's Abrysvo. Arexvy and Abrysvo are approved to prevent RSV-associated lower ...

with protection observed against both RSV A and RSV B subtypes. Three vaccines are currently approved to prevent RSV-LRTD in people aged 60 years or older: an adjuvanted RSV prefusion F protein ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60-74 at high risk. Credit: MargJohnsonVA/Shutterstock ...